about
Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.Platelets: much more than bricks in a breached wall.Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients.Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigmsCommon themes and challenges in hemophilia care: a multinational perspectiveSwitching patients in the age of long-acting recombinant products?High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter studyEmicizumab for hemophilia A without inhibitors
P50
Q39204747-6630326B-104E-4951-90A8-E3CF24E4CCB1Q39248498-98698DBD-62A8-4773-95EF-C8C8D6846F5EQ43706727-FDEAECC6-2EBC-43B0-B3B5-C115FEDB1A6BQ45869705-4961DFA1-275D-4F00-9021-59BD1B9E9949Q90425284-2FC3A17C-E329-4E3C-9238-A40D87AF9A3AQ90732492-B7682D64-7A20-4CC4-B641-21E47925B4E8Q91700182-F5E8A3DF-2CEF-4D63-970B-02A3BF19E5E1Q92247495-41812DCB-56C5-4AEA-B20C-372272CA4601Q92301455-CC322AE5-9D2A-4C4E-8E39-D00D7831F7E1
P50
description
researcher
@en
wetenschapper
@nl
name
Maria Elisa Mancuso
@en
Maria Elisa Mancuso
@nl
type
label
Maria Elisa Mancuso
@en
Maria Elisa Mancuso
@nl
prefLabel
Maria Elisa Mancuso
@en
Maria Elisa Mancuso
@nl
P31
P496
0000-0002-7113-4028